Abstract:It is well accepted that environmental stressors experienced over a one’s life, from microbial infections to chemical toxicants to even psychological stressors, ultimately shape central nervous system (CNS) functioning but can also contribute to its eventual breakdown. The severity, timing and type of such environmental “hits”, woven together with genetic factors, likely determine what CNS outcomes become apparent. This focused review assesses the current COVID-19 pandemic through the lens of a multi-hit frame… Show more
“…Mild encephalopathies with transient symptoms such as altered consciousness (19.1% of 841 patients) or bradypsychia and disorientation (10.1% of 841 patients) were found to occur rather commonly often accompanied by findings of unspecific T2/FLAIR hyperintensity (35% of 20 patients) and ischemic infarcts (31% of 108 patients) in neuroimaging (Romero-Sanchez et al 2020 ; Mahammedi et al 2020 ; Radmanesh et al 2020 ). Severe COVID-19-associated encephalopathies including ADEM or acute necrotizing encephalopathies and poly(radiculo)neuropathies as GBS or other acute neuropathies (multifocal demyelinating or small fiber polyneuropathy) have also been described in several case reports with an estimated prevalence of 0.1–1% in western countries within 6 weeks of confirmed infection (Mahapure et al 2021 ; Parsons et al 2020 ; Shahali et al 2021 ; Toscano et al 2020 ; Camdessanche et al 2020 ; Hayley and Sun 2021 ; Dixon et al 2020 ; Poyiadji et al 2020 ; Oaklander et al 2022 ). For some entities, a causative relationship to prior SARS-CoV-2 infection is less clear.…”
Infection of the CNS with the SARS-CoV-2 can occur via different routes and results in para- or post-infectious manifestations with a variety of neurological symptoms. In patients with neurodegenerative diseases, SARS-CoV-2 is often associated with a higher fatality rate, which is a relevant problem in increasingly older populations. Apart from the direct consequences of an infection in patients with neurodegenerative diseases, indirect consequences of the pandemic such as limited access to care facilities and treatment have negative effects on the course of these chronic disorders. The occurrence of long-lasting neurological symptoms after infection with SARS-CoV-2 indicates a prolonged impact on the CNS. However, while it is known that SARS-CoV-2 affects neuronal populations that are relevant in the pathogenesis of neurodegenerative diseases, it is yet unclear whether an infection with SARS-CoV-2 is sufficient to trigger neurodegeneration. Reflecting on the impact of SARS-CoV-2 on neurodegeneration, we provide a concise overview on the current knowledge of SARS-CoV-2-induced pathology in the CNS and discuss yet open questions in the field.
“…Mild encephalopathies with transient symptoms such as altered consciousness (19.1% of 841 patients) or bradypsychia and disorientation (10.1% of 841 patients) were found to occur rather commonly often accompanied by findings of unspecific T2/FLAIR hyperintensity (35% of 20 patients) and ischemic infarcts (31% of 108 patients) in neuroimaging (Romero-Sanchez et al 2020 ; Mahammedi et al 2020 ; Radmanesh et al 2020 ). Severe COVID-19-associated encephalopathies including ADEM or acute necrotizing encephalopathies and poly(radiculo)neuropathies as GBS or other acute neuropathies (multifocal demyelinating or small fiber polyneuropathy) have also been described in several case reports with an estimated prevalence of 0.1–1% in western countries within 6 weeks of confirmed infection (Mahapure et al 2021 ; Parsons et al 2020 ; Shahali et al 2021 ; Toscano et al 2020 ; Camdessanche et al 2020 ; Hayley and Sun 2021 ; Dixon et al 2020 ; Poyiadji et al 2020 ; Oaklander et al 2022 ). For some entities, a causative relationship to prior SARS-CoV-2 infection is less clear.…”
Infection of the CNS with the SARS-CoV-2 can occur via different routes and results in para- or post-infectious manifestations with a variety of neurological symptoms. In patients with neurodegenerative diseases, SARS-CoV-2 is often associated with a higher fatality rate, which is a relevant problem in increasingly older populations. Apart from the direct consequences of an infection in patients with neurodegenerative diseases, indirect consequences of the pandemic such as limited access to care facilities and treatment have negative effects on the course of these chronic disorders. The occurrence of long-lasting neurological symptoms after infection with SARS-CoV-2 indicates a prolonged impact on the CNS. However, while it is known that SARS-CoV-2 affects neuronal populations that are relevant in the pathogenesis of neurodegenerative diseases, it is yet unclear whether an infection with SARS-CoV-2 is sufficient to trigger neurodegeneration. Reflecting on the impact of SARS-CoV-2 on neurodegeneration, we provide a concise overview on the current knowledge of SARS-CoV-2-induced pathology in the CNS and discuss yet open questions in the field.
“…Curiously, some psychiatric disorders have been linked to excessive activation of the immune system (IS). The release of soluble inflammatory mediators and the mobilization of immune cells can also be stimulated by adequate psychological stressors 12 . Both functional and structural brain alterations 13 such as brain volume loss, astrocyte reduction, and inflammation 14 are commonly related to AN.…”
Section: Introductionmentioning
confidence: 99%
“…It is intuitive that the brain and the IS are the ones mainly responsible for regulating relations with the external environment and have evolved together with the aim of preserving the internal homeostasis of the organism. Therefore, these are systems strictly interconnected in a bidirectional way allowing a balanced and safe relationship of the organism with the environment 12 . AN is associated with a mild inflammatory state, alterations in the immune response, the production of autoantibodies, and occurs during autoimmune diseases, but this is also true in the opposite sense: those affected by autoimmune disorders present similar pathophysiological conditions and can develop anorexia.…”
Section: Introductionmentioning
confidence: 99%
“…The release of soluble inflammatory mediators and the mobilization of immune cells can also be stimulated by adequate psychological stressors. 12 Both functional and structural brain alterations 13 such as brain volume loss, astrocyte reduction, and inflammation 14 are commonly related to AN. We have a lot of evidence of how the IS, along with neurochemical and hormonal responses, can significantly influence central nervous system (CNS) stress circuitry, especially through inflammation molecules.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, these are systems strictly interconnected in a bidirectional way allowing a balanced and safe relationship of the organism with the environment. 12 AN is associated with a mild inflammatory state, alterations in the immune response, the production of autoantibodies, and occurs during autoimmune diseases, but this is also true in the opposite sense: those affected by autoimmune disorders present similar pathophysiological conditions and can develop anorexia. The aim of our work is to bring together the current knowledge on the neuroimmune interaction in AN with new interesting therapeutic perspectives as opened up by the hypothesis of autoimmune mechanisms.…”
Immunological dysfunctions in eating disorders have recently gained increasing scientific attention. Furthermore, the reciprocal association between anorexia and autoimmune diseases is of particular interest and suggests a role of autoimmunity in the pathogenesis of eating disorders. Anorexia nervosa (AN) and autoimmune diseases are linked by a bidirectional relationship based on common immunopathological mechanisms. In this review, in addition to reporting the numerous cases described in which autoimmune disorders are associated with anorexia or vice versa, we summarize the many aspects of this relationship between the immune system (IS) and AN. We describe how the microbiota affects the IS, disrupts gut‐brain communication, and possibly triggers eating disorders. We also describe the shared immunological pathways of autoimmune and eating disorders and in particular the occurrence of disrupted T cell tolerance and autoantibodies in AN. The described observations represent the starting point for possible, future research directions.
Acknowledging the neurological symptoms of COVID‐19 and the long‐lasting neurological damage even after the epidemic ends are common, necessitating ongoing vigilance. Initial investigations suggest that extracellular vesicles (EVs), which assist in the evasion of the host's immune response and achieve immune evasion in SARS‐CoV‐2 systemic spreading, contribute to the virus's attack on the central nervous system (CNS). The pro‐inflammatory, pro‐coagulant, and immunomodulatory properties of EVs contents may directly drive neuroinflammation and cerebral thrombosis in COVID‐19. Additionally, EVs have attracted attention as potential candidates for targeted therapy in COVID‐19 due to their innate homing properties, low immunogenicity, and ability to cross the blood‐brain barrier (BBB) freely. Mesenchymal stromal/stem cell (MSCs) secreted EVs are widely applied and evaluated in patients with COVID‐19 for their therapeutic effect, considering the limited antiviral treatment. This review summarizes the involvement of EVs in COVID‐19 neuropathology as carriers of SARS‐CoV‐2 or other pathogenic contents, as predictors of COVID‐19 neuropathology by transporting brain‐derived substances, and as therapeutic agents by delivering biotherapeutic substances or drugs. Understanding the diverse roles of EVs in the neuropathological aspects of COVID‐19 provides a comprehensive framework for developing, treating, and preventing central neuropathology and the severe consequences associated with the disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.